Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
635 artigos
A Dana-Farber review maps the path for personalized cancer vaccines — pinpointing which tumors, timing, and combination strategies will matter most.
Peter Attia breaks down why colorectal cancer is one of the most preventable cancers and how to build a personalized screening strategy.
Path2Space uses deep learning to infer spatial gene expression from standard tissue slides, enabling low-cost breast cancer biomarker discovery at scale.
A completed Phase 2 trial tests UCPVax cancer vaccine combined with atezolizumab in cervical, anal, and head-and-neck cancers.
A Lancet commentary reexamines the true preventive benefit of colonoscopy screening, challenging assumptions about how we calculate cancer risk reduction.
A completed phase I trial tests regorafenib plus dual checkpoint inhibitors in 39 patients with hard-to-treat metastatic colorectal cancer.
A completed Phase 2 trial tests nivolumab plus ipilimumab in CDK12-mutant metastatic prostate and solid tumors across 56 patients.
A novel immune-evasion mechanism in triple-negative breast cancer reveals how cancer stem cells suppress anti-tumor immunity via extracellular vesicles.
A triple immunotherapy unlocks anti-tumor CD4+ T cells — not CD8+ — to clear pancreatic tumors in mice, reshaping the immunotherapy playbook.
High-level randomized evidence quantifies genitourinary toxicity burden over time following prostate radiotherapy, with direct implications for treatment decisions.
Ficerafusp alfa plus pembrolizumab shows striking results in HPV-negative head and neck cancer, a notoriously difficult-to-treat population.
Researchers identify four LSC subtypes that predict venetoclax resistance and reveal matched subtype-specific therapies for AML patients.
